CSTL Earnings & Financial Statements
Castle Biosciences, Inc.
$33.80
+$0.69(+2.09%)
57
Overall
60
Value
54
Tech
57
Quality
Market Cap
$1.01B
Volume
77.48K
52W Range
$17.72 - $44.28
Target Price
$45.11
CSTL earnings and financial statements: Castle Biosciences, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
CSTL Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $344.23M | $332.07M | $219.79M | $137.04M | $94.08M |
| Cost of revenue | $71.03M | $60.20M | $44.98M | $32.01M | $15.82M |
| Operating income | -$42.81M | $8.67M | -$67.98M | -$72.86M | -$40.08M |
| EBITDA | $11.34M | $38.14M | -$45.02M | -$58.34M | -$36.60M |
| Net income | -$24.16M | $18.25M | -$57.47M | -$67.14M | -$31.29M |
| EPS (diluted) | $-0.83 | $0.62 | $-2.14 | $-2.58 | $-1.24 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $578.56M | $531.24M | $453.34M | $447.33M | $462.57M |
| Total liabilities | $107.68M | $75.40M | $62.07M | $48.18M | $50.83M |
| Shareholders’ equity | $470.87M | $455.83M | $391.27M | $399.15M | $411.74M |
| Cash and equivalents | $116.70M | $119.71M | $98.84M | $122.95M | $329.63M |
| Long-term debt | $35.17M | $24.40M | $14.20M | $11.53M | $6.90M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | $64.35M | $64.87M | -$5.63M | -$41.66M | -$18.98M |
| Capital expenditure | -$35.98M | -$28.31M | -$13.62M | -$5.63M | -$3.48M |
| Free cash flow | $28.33M | $36.54M | -$19.25M | -$47.29M | -$22.47M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | CSTL | $33.80 | +2.1% | 77.48K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Castle Biosciences, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW